Prognostic implications of risk definitions from the monarchE and NATALEE trials.
AuteursArecco L, Blondeaux E, Bruzzone M, Arpino G, De Angelis C, De Laurentiis M, Caputo R, Fabi A, Sanna V, Gori S, Puglisi F, Boni L, Nardin S, Giannubilo I, Perachino M, Borea R, Agostinetto E, de Azambuja E, Lambertini M, Del Mastro L
Are Patients with Prostate Imaging Reporting and Data System 5 Lesions Eligible for Active Surveillance? A Multicentric European Study.
AuteursPeyrottes A, Baboudjian M, Diamand R, Ducrot Q, Vitard C, Baudewyns A, Windisch O, Anract J, Dariane C, Tricard T, Sarkis J, Sadreux Y, Oderda M, Depaquit TL, La Taille A, Olivier J, Brureau L, Rouviere O, Crouzet S, Ruffion A, Desgrandchamps F, Roumiguie M, Rouprêt M, Ploussard G, Fiard G
Are Patients with Prostate Imaging Reporting and Data System 5 Lesions Eligible for Active Surveillance? A Multicentric European Study.
AuteursPeyrottes A, Baboudjian M, Diamand R, Ducrot Q, Vitard C, Baudewyns A, Windisch O, Anract J, Dariane C, Tricard T, Sarkis J, Sadreux Y, Oderda M, Depaquit TL, La Taille A, Olivier J, Brureau L, Rouviere O, Crouzet S, Ruffion A, Desgrandchamps F, Roumiguie M, Rouprêt M, Ploussard G, Fiard G
Duodenal Organoids From Metabolic Dysfunction-Associated Steatohepatitis Patients Exhibit Absorptive and Barrier Alterations.
AuteursHadefi A, Leprovots M, Dinsart G, Marefati M, Vermeersch M, Monteyne D, Pérez-Morga D, Lefort A, Libert F, Verset L, Liefferinckx C, Moreno C, Devière J, Trépo E, Garcia MI
Cardiovascular Safety in Oncology Clinical Trials: JACC: CardioOncology Primer.
AuteursBonaca MP, Lang NN, Chen A, Amiri-Kordestani L, Lipka L, Zwiewka M, Strnadova C, Klaar S, Dent S, Janicijevic TK, Herrmann J, Barac A, de Boer RA, Deswal A, Schou M, Neilan TG, van der Meer P, Moslehi J, Kondapalli L, Ky B, Fernandez TL, Cornell RF, Flaig TW, Hsia J, Sharon E, de Azambuja E, Seltzer J, Januzzi JL, Petrie MC
Combination of Brentuximab Vedotin and Pembrolizumab as Salvage Treatment Before Autologous Stem Cell Transplantation and Maintenance in Patients with Relapsed/Refractory Hodgkin Lymphoma.
Combination of Brentuximab Vedotin and Pembrolizumab as Salvage Treatment Before Autologous Stem Cell Transplantation and Maintenance in Patients with Relapsed/Refractory Hodgkin Lymphoma.
Combination of Brentuximab Vedotin and Pembrolizumab as Salvage Treatment Before Autologous Stem Cell Transplantation and Maintenance in Patients with Relapsed/Refractory Hodgkin Lymphoma.
Clinical Behavior of Breast Cancer in Young <i>BRCA</i> Carriers and Prediagnostic Awareness of Germline <i>BRCA</i> Status.
AuteursLambertini M, Blondeaux E, Tomasello LM, Agostinetto E, Hamy AS, Kim HJ, Franzoi MA, Bernstein-Molho R, Hilbers F, Pogoda K, Wildiers H, Bajpai J, Ignatiadis M, Moore HCF, Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Criscitiello C, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Puglisi F, Rodriguez-Wallberg KA, Duhoux FP, Livraghi L, Bruzzone M, Boni L, Balmaña J
